Navicixizumab Biosimilar Bispecific Antibody (DLL4 × VEGF-A) for Research
Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Navicixizumab is an anti-DLL4/VEGF bispecific antibody that has demonstrated robust in vivo antitumor efficacy in a number of solid tumor xenografts. In the phase Ia trial of the monotherapy, 66 patients with various solid tumors were treated once every 3 weeks in 1 of 8 dose-escalation cohorts or an expansion cohort.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-369-1mg | 1mg | |
| GMP-Bios-ab-369-10mg | 10mg | |
| GMP-Bios-ab-369-100mg | 100mg | |
| GMP-Bios-ab-369-xmg | >100mg |
Product Details
| Products Name (INN Index) | Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody |
| INN Name | Navicixizumab |
| Target | DLL4;VEGFA |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | OncoMed Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer |
| Conditions Discontinued | Colorectal cancer;Solid tumours |
| Development Tech | na |
About target - DLL4
1. Protein Leukocyte immunoglobulin-like receptor subfamily A member 4
2. Gene LILRA4
3. Organism Homo sapiens (Human)
Function
Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354).
Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades (PubMed:16735691, PubMed:19564354, PubMed:24586760).
Down-regulates interferon production in response to interaction with BST2 on HIV-1 infected cells (PubMed:26172439).
Activates a signaling cascade in complex with FCER1G that results in phosphorylation of Src family and Syk kinases and thereby triggers mobilization of intracellular Ca2+ (PubMed:16735691, PubMed:19564354).
Does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells (PubMed:24586760).

